Axoltis Pharma

Executive Summary

Axoltis Pharma is a French biopharmaceutical company founded in 2019 and headquartered in Lyon, dedicated to developing first-in-class therapies for degenerative and traumatic neurological disorders with high unmet medical needs. Its lead candidate, NX210c, is a therapeutic peptide designed to promote central nervous system regeneration, primarily targeting spinal cord injury and potentially other CNS conditions. The company operates in the RNA & Gene Therapy sector but focuses on peptide-based approaches. As a private entity with limited disclosed funding and clinical progress, Axoltis Pharma is at an early stage, likely in preclinical development or preparing for initial clinical trials. Its innovative approach addresses a critical gap in CNS repair, where few effective treatments exist. The company’s success hinges on advancing NX210c through preclinical studies and into human trials, with potential for significant impact in neurology.

Upcoming Catalysts (preview)

• Q4 2026IND/CTA filing for NX210c60% success
• Q2 2027First patient dosed in Phase 1 trial50% success
• Q3 2026Publication of preclinical efficacy data70% success